Replies to post #511134 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

You should take a look at what UCLA's using in the trial, they never refer to it as DCVax-L, but that's what they're making right at UCLA. Once it is approved I really don't know if they'll continue as they are, or if they'll go to NWBO for the vaccine. Perhaps someone knows what's in the fine print in the agreement between NWBO and UCLA, I certainly don't, but if there is anyone who's permitted to make the vaccine for themselves once it's approved it ought to be UCLA.

Gary

[hoffmann6383]

lol, yes, ucla is treating dcvax-l as the SoC in their ongoing trials

[Roman516]

The real truth of the DCVax-L matter

Not true
"DCVax-L is NOT the standard of care in Dr. Liau's SPORE Keytruda/ATL combination trial -- it is the comparator arm."

True
DCVax-L is the base product for the standard of care in Dr. Liau's SPORE Keytruda/ATL combination trial -- it is the comparator arm.

So, you agree that DCVax-L will in fact be used in the standard of care, and this "Treatment has been accepted by a number of medical experts as a proper treatment for a certain type of cancer disease and that it is the desire to be widely used by healthcare professionals."

DCVax-L works and should be approved so it can be the standard of care. Clear enough? Yes indeed, thanks for the real clarification.

[SkyLimit2022]

Yes, DCVax is filling the role of SOC in the Keytruda trial …

NCI, Merck, & PHASE ONE are today supporting collaborators on the UCLA Keytruda trial—100% of patients in both the experimental group AND the placebo group receive DCVax. Only Keytruda in combo is being investigated—everyone receives DCVax as if it were SOC.

Group A (pembrolizumab, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

Group B (placebo, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

virtualtrials.org/dcvax.cfm

https://clinicaltrials.gov/ct2/show/NCT04201873

[SkyLimit2022]

DCVax is filling the role of SOC in the Keytruda trial—you misunderstood—it is filling the role of SOC within the trial because every patient in both the experimental arm as well as the placebo arm are receiving DCVax-L.

NCI, Merck, & PHASE ONE are today supporting collaborators on the UCLA Keytruda trial—100% of patients in both the experimental group AND the placebo group receive DCVax. Only Keytruda in combo is being investigated—everyone receives DCVax as if it were SOC.

Group A (pembrolizumab, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

Group B (placebo, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

virtualtrials.org/dcvax.cfm

https://clinicaltrials.gov/ct2/show/NCT04201873